Clinical Trials
2 trialsNCT05941637 2024-12-31
An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)
Lynkcell Europe
No longer available
NCT01473043 2014-05-30
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
Pfizer
No longer available